203 related articles for article (PubMed ID: 11176457)
1. Bacillus Calmette-Guerin induces long-term local formation of nitric oxide in the bladder via the induction of nitric oxide synthase activity in urothelial cells.
Morcos E; Jansson OT; Adolfsson J; Ehrén I; Wiklund NP
J Urol; 2001 Feb; 165(2):678-82. PubMed ID: 11176457
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
[TBL] [Abstract][Full Text] [Related]
3. The effect of intravesical Bacillus Calmette-Guerin instillations on the expression of inducible nitric oxide synthase in humans.
Mitropoulos D; Petsis D; Kyroudi-Voulgari A; Kouloukoussa M; Zervas A; Dimopoulos C
Nitric Oxide; 2005 Aug; 13(1):36-41. PubMed ID: 15964223
[TBL] [Abstract][Full Text] [Related]
4. Bacille-Calmette Guèrin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1.
See WA; Zhang G; Chen F; Cao Y; Langenstroer P; Sandlow J
BJU Int; 2009 Jun; 103(12):1714-20. PubMed ID: 19154459
[TBL] [Abstract][Full Text] [Related]
5. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
6. [Study on Toll-like receptors expression and cytokine production induced by bacillus Calmette-Guerin in human bladder cancer cell].
Li X; Gong ZY; Li H; Wei Q; Shi M; Yang YR
Zhonghua Wai Ke Za Zhi; 2004 Feb; 42(3):177-81. PubMed ID: 15062066
[TBL] [Abstract][Full Text] [Related]
7. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.
Dovedi SJ; Kirby JA; Atkins H; Davies BR; Kelly JD
J Urol; 2005 Jul; 174(1):332-7; discussion 337. PubMed ID: 15947685
[TBL] [Abstract][Full Text] [Related]
9. Systemic and local immunomodulatory effects of intravesical BCG therapy in patients with superficial urinary bladder carcinomas.
Elsässer-Beile U; Gutzeit O; Bauer S; Katzenwadel A; Schultze-Seemann W; Wetterauer U
J Urol; 2000 Jan; 163(1):296-9. PubMed ID: 10604379
[TBL] [Abstract][Full Text] [Related]
10. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
Chen F; Zhang G; Cao Y; Hessner MJ; See WA
J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
[TBL] [Abstract][Full Text] [Related]
11. Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette-Guérin.
Zhang G; Chen F; Cao Y; See WA
J Urol; 2013 Oct; 190(4):1398-403. PubMed ID: 23583857
[TBL] [Abstract][Full Text] [Related]
12. N-acetylcysteine augments the cellular redox changes and cytotoxic activity of internalized mycobacterium bovis in human bladder cancer cells.
Pook SH; Esuvaranathan K; Mahendran R
J Urol; 2002 Aug; 168(2):780-5. PubMed ID: 12131368
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
14. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
15. The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer.
Jansson OT; Morcos E; Brundin L; Lundberg JO; Adolfsson J; Söderhäll M; Wiklund NP
Br J Cancer; 1998 Sep; 78(5):588-92. PubMed ID: 9744496
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Chen F; Zhang G; Cao Y; Payne R; See WA
J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
[TBL] [Abstract][Full Text] [Related]
18. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
[TBL] [Abstract][Full Text] [Related]
19. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Böhle A; Brandau S
J Urol; 2003 Sep; 170(3):964-9. PubMed ID: 12913751
[TBL] [Abstract][Full Text] [Related]
20. Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
Herr HW; Dalbagni G
J Urol; 2003 May; 169(5):1706-8. PubMed ID: 12686813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
